0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

UV-A1 Therapy for Nephrogenic Systemic Fibrosis FREE

Kien T. Tran, MD, PhD; Heidi B. Prather, BS; Clay J. Cockerell, MD; Heidi Jacobe, MD
[+] Author Affiliations

Author Affiliations: Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.


Arch Dermatol. 2009;145(10):1170-1174. doi:10.1001/archdermatol.2009.245.
Text Size: A A A
Published online

ABSTRACT

Background  Nephrogenic systemic fibrosis (NSF) is a rare sclerosing skin condition associated with end-stage renal disease and gadolinium exposure. Therapy for NSF is challenging, with few options other than preventing exposure to gadolinium and improving renal function through transplant. However, in some cases neither of these options is tenable. We report the successful use of UV-A1 phototherapy in 4 patients with NSF.

Observations  Four patients with NSF were treated with UV-A1 phototherapy at a tertiary medical center from 2005 through 2007. To our knowledge, it is unique to this series that all patients were receiving hemodialysis before, during, and after therapy with UV-A1. All experienced improvement in the degree of induration, and 2 experienced improvement in mobility of the hands and legs. Total treatments ranged from 22 treatments (with a cumulative dose of 1855 J/cm2) to 50 treatments (total UV-A1 exposure, 3850 J/cm2). No adverse events were observed.

Conclusions  Although no patient had complete resolution of indurated plaques, the improvement was substantial. For 2 patients, it resulted in a resumption of hand and leg mobility. As a result, UV-A1 therapy may represent a treatment for NSF when kidney transplantation is not an option or is delayed. Limitations of this study include the lack of a controlled trial, lack of quantification of gadolinium levels within tissue, and the lack of a defined grading scale for NSF severity.

Figures in this Article

Originally designated nephrogenic fibrosing dermopathy, nephrogenic systemic fibrosis (NSF) is a rare, sclerosing skin condition that usually occurs in the setting of renal insufficiency, especially chronic kidney disease requiring hemodialysis.19 Exposure to gadolinium, especially the gadodiamide form, has been implicated in almost all cases of NSF.10 Lesions are initially usually edematous, erythematous plaques on the distal extremities.11 Over time, they develop a woody induration with a cobblestone appearance. Nephrogenic systemic fibrosis may rarely involve extracutaneous sites such as skeletal muscle, the diaphragm, and myocardium.1215 Pruritus, pain, and burning accompany NSF, along with loss of joint mobility.

No definitive treatment for NSF exists. Because it is rare, the existing literature consists of case reports or case series. Currently, prevention of exposure to gadolinium in patients with renal impairment is considered ideal. Improvement in renal function is associated with involution of NSF lesions in some cases.1623 Thus, transplantation is a potential means of therapy.24 Extracorporeal photopheresis (ECP) is another modality with the some supporting evidence for efficacy.2530 Case reports of treatments with varying success include imatinib mesylate, plasmapharesis, intravenous immunoglobin, topical steroids, topical calicipotriene, and oral immunosuppressants such as methotrexate.31,32 Other reported treatments include psoralen UV-A (PUVA) and photodynamic therapy.30,3335 These modalities all have significant drawbacks, including their invasive nature, the cost of ECP, problems with polypharmacy, and immunosuppression in a population with clinically significant preexisting morbidity. Ultraviolet A1 phototherapy is attractive because it avoids these issues.

Ultraviolet light therapy in the long-wave UV-A range (340-400 nm) is a potentially viable treatment option for NSF because of its deep penetration into the dermis and superficial part of the subcutis.36,37 In addition, UV-A1 is used successfully in other sclerosing skin conditions, including localized scleroderma, systemic sclerosis, and chronic sclerodermoid graft vs host disease.38 There is 1 prior case report of the successful use of UV-A1 phototherapy in NSF.39 However, the patient had transient renal compromise and did not require hemodialysis. This makes it difficult to determine if improvement was the result of normalization of renal function or UV-A1. Herein, we report the use of UV-A1 therapy to treat 4 patients with NSF. Unique to these cases is the chronicity of hemodialysis. All patients were undergoing hemodialysis prior to, during, and after treatment with UV-A1, with no notable change in renal function.

METHODS

From 2005 through 2007, 4 patients with NSF were evaluated at the University of Texas–Southwestern (UTSW) Medical Center in Dallas. All shared clinical and histologic features supporting the diagnosis of NSF along with a medical history of end-stage renal disease (ESRD) requiring hemodialysis. In all patients, hemodialysis protocols remained unaltered during and after treatment with UV-A1. Patient characteristics and outcome are outlined in the following case summaries and in the Table.

All patients were treated with a UV-A1 bed (Sellamed Systems, model 24000; Sellamed, Gevelsberg, Germany). Output for this device is 5 J/cm2 per minute. Patients were treated 3 times per week beginning with a low to medium dose (30-60 J/cm2) increasing to a high dose (120 J/cm2) of UV-A1. The starting dose was determined by Fitzpatrick skin type. The dosage was increased by 10 J/cm2 per visit as long as no erythema occurred. If mild erythema occurred, the dose was maintained. If moderate erythema occurred, the dose was lowered to the prior level. Standard safety precautions, including the use of protective eyewear, were maintained. All patients were treated and evaluated by the same physician (H.J.). Improvement was ascertained by the ability to make a fist; the range of motion at the ankle, knee, waist, and elbow; the ability to ambulate; degree of induration by palpation; and the progression of lesions before and after treatment.

RESULTS

CASE 1

Patient 1 was a 62-year-old white woman with a history of alpha-1-antitrypsin deficiency requiring a lung transplant in 1995 with renal insufficiency. She was admitted in 2006 for acute renal failure thought to be related to the toxic effects of tacrolimus. During this admission, she received a magnetic resonance imaging (MRI) scan with gadodiamide contrast for evaluation of altered mental status. Hemodialysis was started simultaneously. After 3 weeks, she developed erythematous, edematous plaques with some desquamation on her extensor and volar forearms, legs, thighs, and buttocks. She complained of pruritus and burning along with loss of range of motion in her ankles and hands. Findings from her biopsy specimen were consistent with clinically suspected NSF. Workup by a rheumatologist included an antinuclear antibody (ANA) profile and a double-stranded DNA profile. Findings from both tests were negative. She did not meet diagnostic criteria for scleroderma. After 2 months, UV-A1 therapy was instituted at 30 J/cm2. At the time treatment was initiated, the patient had experienced progressively worsening induration of her extremities. She could weakly twitch her fingers but was unable to make a fist and had limited mobility at the knee and ankle, resulting in difficulty in walking. Within 10 treatments at a total dose of 505 J/cm2, the patient noted a decrease in the sclerosis and edema of her arms and legs along with decreased pruritus and burning. After 50 treatments (total dose, 3850 J/cm2), she was able to nearly make a fist. She continued to experience induration of her legs, but her range of motion was improved, and progression of the disease had halted. Ultraviolet A1 therapy was discontinued, and the patient continued to receive physical therapy to increase the mobility in her hands. One year after UV-A1 therapy was discontinued, her condition remained stable, with no recurrence of disease activity. She was able to make a fist and experienced continued improvement in range of motion at the knee and ankle along with improved ambulation.

CASE 2

Patient 2 was a 72-year-old white woman with a history of hypertension resulting in ESRD who had been undergoing hemodialysis for 3 months prior to developing erythematous, tender plaques on her upper and lower extremities. The patient had received an MRI scan with gadodiamide contrast 5 months prior. On examination, her left arm and forearm had greater involvement than her right. Her calves had plaques covering the lateral and posterior surfaces. Her range of motion was intact in the upper and lower extremities. Findings from a biopsy were compatible with the clinical suspicion for NSF. Findings from a workup for scleroderma, including ANA, anti-scl70, and anticentromere antibody profiles, were negative. Previous treatment included triamcinolone acetonide cream without improvement, and actual progression of the lesions. Treatment with UV-A1 was started at a dose of 60 J/cm2 2 months after the onset of NSF. At follow-up after 16 treatments, the patient experienced notable improvement with decreased induration, and disease progression was halted. Ultraviolet A1 therapy was discontinued at the patient's request owing to improvement and problems with travel. One year after discontinuing UV-A1 therapy, the patient maintained improvement without development of new lesions.

CASE 3

Patient 3 was a 57-year-old Hispanic woman with a history of diabetes mellitus, hypertension, and hepatitis C who had been undergoing long-term hemodialysis for ESRD secondary to diabetic nephropathy. She had an MRI scan with gadopentate dimeglumine, with onset of lesions shortly thereafter. She was initially treated with antibiotics for presumed cellulitis but had no other treatment. Her initial evaluation at UTSW Medical Center occurred 2 years after she had developed contiguous woody plaques on the upper and lower extremities, sparing the trunk. Her lesions impaired daily function with severe involvement of her popliteal fossa and ankles, resulting in an inability to walk and a very limited range of motion of the wrists and elbows. Biopsy findings, along with clinical presentation, were consistent with NSF. Therapy with UV-A1 was instituted at 60 J/cm2. After 32 sessions, she was noted to have softening in the popliteal fossa with ability to extend the legs and improved mobility. The treatments were continued for 41 sessions (total dose, 4065 J/cm2). She also received physical therapy. After discontinuation of UV-A1, she did not have recurrence or progression of her NSF (remission) and had regained her ability to walk. This was maintained up to 6 months after discontinuation of UV-A1; thereafter the patient was lost to follow-up.

CASE 4

Patient 4 was a 71-year-old African American woman with a history of hypertension resulting in ESRD who had been undergoing hemodialysis for 3 months when she developed erythematous, tender plaques on the forearm of the left arm along with bilateral involvement of the posterior arms, thighs, and legs (Figure 1). The plaques occurred a few months after the patient underwent MRI with gadolinium contrast and, over time, developed woody induration. Biopsy findings were consistent with NSF (Figure 2). Ultraviolet A1 therapy was instituted at a dosage of 60 J/cm2. Follow-up at treatment 9 (total dose, 1160 J/cm2) showed improvement in induration. At treatment 22 (total dose, 3310 J/cm2), UV-A1 phototherapy was discontinued owing to considerable improvement in existing lesions and apparent remission of active disease. The improvement was maintained during 9 months of follow-up.

Place holder to copy figure label and caption
Figure 1

Nephrogenic systemic fibrosis in patient 4. Erythematous indurated and tender plaques with scale on the midthigh on initial presentation.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Punch biopsy specimen of an indurated plaque. A prominent deep dermal proliferation of numerous, slender, spindled cells with extension along the interlobular septae of the subcutaneous fat exists. There are minimal lymphocytes in the interlobular septae and a suggestion of mucin between the proliferating spindled cells. The cells stained dually for CD34 and procollagen I. Colloidal iron stain suggested a foci of mucin (original magnification ×20).

Graphic Jump Location

COMMENT

This case series comprised 4 patients with NSF who were treated successfully with UV-A1 therapy. All of the patients had exposure to gadolinium either concurrent with or before development of cutaneous signs suggestive of NSF. Patients had histologic evidence supporting NSF to verify the clinical findings. No patient developed signs of systemic involvement that would necessitate systemic treatment in place of or in addition to UV-A1 phototherapy. To our knowledge, it is unique to this case series that all patients were diagnosed as having ESRD and were receiving hemodialysis before, during, and after presentation with NSF. Cutaneous improvement did not occur until after institution of UV-A1 therapy. After UV-A1 therapy was discontinued, no patient had a relapse, nor did any patient have spontaneous continued improvement (patients were in remission).

Within our study, all patients had experienced improvement in induration with a decrease in pain and pruritus. For patients 1 and 3, the concomitant increase in joint mobility resulted in an enhanced quality of life that was the major therapeutic benefit of UV-A1 therapy. However, none had complete resolution of cutaneous findings. This might relate to premature discontinuation of therapy in some cases. All had difficulty maintaining triweekly appointment schedules in light of their ongoing hemodialysis. Another possibility might be the inability of UV-A1 to penetrate to the entire depth of the lesion.40

The mechanism of action of UV-A1 in the treatment of NSF is unclear. In other sclerotic conditions, such as systemic sclerosis, there is an increase in type I and type III collagen.41,42 In scleroderma, UV-A1 radiation seems to increase synthesis of collagenase I in vitro and in vivo in fibroblasts.43,44 Along with this, UV irradiation inhibits procollagen synthesis in human skin.45 Kafi et al46 were able to demonstrate elevated procollagen I and III messenger RNA (mRNA) levels along with an increased mRNA level in the upstream signaling elements of transforming growth factor β and connective growth factor in NSF.46 Twelve weeks of UV-A1 phototherapy resulted in a decrease in induration along with normalization of the mRNA levels of these cytokines and procollagen in the same report by Kafi et al.46 This would suggest that UV-A1 therapy alters the cytokine levels relating to fibrocytes to promote a less fibrotic environment. Also, initiation of UV-A1 early in the development of NSF is of greater benefit.

No therapy, including renal transplant, is totally effective in the treatment of NSF. In lieu of a renal transplant, ECP is currently the treatment option with the most supporting data.47 Although ECP is a well-tolerated procedure, it is more invasive than UV light therapy, requiring large-bore peripheral venous access or central venous access. Adverse effects from ECP include hypotension, flulike symptoms, and anemia.48 Extracorporeal photopheresis is also more costly than UV-A1. Psoralen–UV-A therapy has also shown promise in the treatment of NSF, but utilization of PUVA requires oral ingestion of psoralens and concomitant adverse effects. Furthermore, patients undergoing hemodialysis are routinely prescribed a polypharmacy regimen, which increases the risk of a drug-drug interaction. Ultraviolet-A1 phototherapy is noninvasive and does not require the use of systemic medications. One issue, however, is that currently UV-A1 therapy is not widely available in the United States.

Herein, we describe a series of 4 patients with NSF treated successfully with UV-A1 phototherapy. Unlike the prior case report by Kafi et al,46 the patients were all diagnosed as having ESRD and were undergoing hemodialysis during and after UV-A1 therapy with no change in their renal status during therapy. Although none had complete resolution, all had notable improvement, with 2 showing a return of joint mobility with considerable quality-of-life improvement. The earliest documented improvement for our series occurred within 3 weeks or 9 treatments, with peak improvement occurring after 41 to 50 treatments. Owing to the rapidity and ease with which phototherapy can be instituted, we advocate that UV-A1 phototherapy be considered a potential treatment option for patients with NSF where it is available. Although promising, our data are limited to a case series. One disadvantage in our case series is the lack of a scoring system, such as the Rodnan skin scoring system, for objectively measuring involvement before and after UV-A1 therapy. Furthermore, quantification of gadolinium with measurement of changes, if any, during therapy would be of interest in further ascertaining the potential mechanism of action of UV-A1 phototherapy in NSF. Finally, future investigations should include a controlled trial comparing the current treatment modalities.

ARTICLE INFORMATION

Correspondence: Heidi Jacobe, MD, Department of Dermatology, University of Texas–Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9069 (heidi.jacobe@utsouthwestern.edu).

Accepted for Publication: May 31, 2009.

Author Contributions: Dr Jacobe had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Tran and Jacobe. Acquisition of data: Tran and Prather. Analysis and interpretation of data: Tran, Cockerell, and Jacobe. Drafting of the manuscript: Tran, Prather, and Jacobe. Critical revision of the manuscript for important intellectual content: Tran and Jacobe. Administrative, technical, and material support: Cockerell and Jacobe. Study supervision: Jacobe. Dermatopathology: Cockerell and Tran.

Financial Disclosure: None reported.

REFERENCES

Jiménez  SAArtlett  CMSandorfi  N  et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50 (8) 2660- 2666
PubMed Link to Article
Mendoza  FAArtlett  CMSandorfi  NLatinis  KPiera-Velazquez  SJimenez  SA Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35 (4) 238- 249
PubMed Link to Article
Swartz  RDCrofford  LJPhan  SHIke  RWSu  LD Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114 (7) 563- 572
PubMed Link to Article
Cassis  TBJackson  JMSonnier  GBCallen  JP Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 2006;45 (1) 56- 59
PubMed Link to Article
Marckmann  PSkov  LRossen  K  et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17 (9) 2359- 2362
PubMed Link to Article
Marckmann  PSkov  LRossen  KHeaf  JGThomsen  HS Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22 (11) 3174- 3178
PubMed Link to Article
Dundová  ITreska  VSimanek  VMichal  M Nephrogenic fibrosing dermopathy: a case study. Transplant Proc 2005;37 (10) 4187- 4190
PubMed Link to Article
Schmook  TBudde  KUlrich  CNeumayer  HHFritsche  LStockfleth  E Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005;20 (1) 220- 222
PubMed Link to Article
Sadowski  EABennett  LKChan  MR  et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243 (1) 148- 157
PubMed Link to Article
Penfield  JGReilly  RF Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008;21 (2) 129- 134
PubMed Link to Article
Cowper  SE Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15 (6) 785- 790
PubMed Link to Article
Cowper  SEBoyer  PJ Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006;8 (2) 151- 157
PubMed Link to Article
Kucher  CSteere  JElenitsas  RSiegel  DLXu  X Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006;54 (2) (suppl)S31- S34
PubMed Link to Article
Gibson  SEFarver  CFPrayson  RA Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130 (2) 209- 212
PubMed
Saenz  AMandal  RKradin  RHedley-Whyte  ET Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006;449 (3) 389- 391
PubMed Link to Article
Maloo  MAbt  PKashyap  R  et al.  Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006;6 (9) 2212- 2217
PubMed Link to Article
Kay-Wiggan  JMCohen  DJHardy  MA  et al.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48 (1) 55- 60
Link to Article
Jan  FSegal  JMDyer  JLeBoit  PSiegfried  EFrieden  IJ Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003;143 (5) 678- 681
PubMed Link to Article
Introcaso  CEHivnor  CCowper  SWerth  VP Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol 2007;46 (5) 447- 452
PubMed Link to Article
Collidge  TAThomson  PCMark  PB  et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245 (1) 168- 175
PubMed Link to Article
Richmond  HZwerner  JKim  YFiorentino  D Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007;143 (8) 1025- 1030
PubMed Link to Article
Knopp  EACowper  SE Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21 (2) 123- 128
PubMed Link to Article
Gilliet  MCozzio  ABurg  GNestle  FO Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005;152 (3) 531- 536
PubMed Link to Article
Auron  AShao  LWarady  BA Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006;21 (9) 1307- 1311
PubMed Link to Article
Läuchli  SZortea-Caflisch  CNestle  FOBurg  GKempf  W Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004;208 (3) 278- 280
PubMed Link to Article
Kay  JHigh  WA Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008;58 (8) 2543- 2548
PubMed Link to Article
Hubbard  VDavenport  AJarmulowicz  MRustin  M Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003;148 (3) 563- 568
PubMed Link to Article
Ting  WWStone  MSMadison  KCKurtz  K Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139 (7) 903- 906
PubMed Link to Article
Lim  HWHonigsmann  HHawk  JLM Photodermatology.  New York, NY: InformaHealthcare USA; 2007
Dawe  RS Ultraviolet A1 phototherapy. Br J Dermatol 2003;148 (4) 626- 637
PubMed Link to Article
Kafi  RFisher  GJQuan  T  et al.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140 (11) 1322- 1324
PubMed Link to Article
Rodnan  GPLipinski  ELuksick  J Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22 (2) 130- 140
PubMed Link to Article
Takehara  KMoroi  YNakabayashi  YIshibashi  Y Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26 (5) 612- 616
PubMed Link to Article
Scharffetter  KWlaschek  MHogg  A  et al.  UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991;283 (8) 506- 511
PubMed Link to Article
Petersen  MJHansen  CCraig  S Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992;99 (4) 440- 444
PubMed Link to Article
Fisher  GJDatta  SWang  Z  et al.  c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000;106 (5) 663- 670
PubMed Link to Article
McKenna  KEWhittaker  SRhodes  LE  et al. British Photodermatology Group; UK Skin Lymphoma Group, Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006;154 (1) 7- 20
PubMed Link to Article
Dawe  RS Ultraviolet A1 phototherapy. Br J Dermatol 2003;148 (8) 626- 637
Link to Article
Kafi  RFisher  GJQuan  T  et al.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140 (11) 1322- 1324
Link to Article
Mendoza  FAArtlett  CMSandorfi  N  et al.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35 (4) 238- 249
Link to Article
Rodnan  GPLipinski  ELuksick  J Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22 (2) 130- 140
Link to Article
Takehara  KMoroi  YNakabayashi  Y  et al.  Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26 (5) 612- 616
Link to Article
Scharffetter  KWlaschek  MHogg  A  et al.  UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991;283 (8) 506- 511
Link to Article
Petersen  MJHansen  CCraig  S Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992;99 (4) 440- 444
Link to Article
Fisher  GJDatta  SWang  Z  et al.  c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000;106 (5) 663- 670
Link to Article
Kafi  RFisher  GJQuan  T  et al.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140 (11) 1322- 1324
Link to Article
Knopp  EA Cowper, SE Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21 (2) 123- 128
Link to Article
McKenna  KEWhittaker  SRhodes  LE  et al.  Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006;154 (1) 7- 20
Link to Article

Figures

Place holder to copy figure label and caption
Figure 1

Nephrogenic systemic fibrosis in patient 4. Erythematous indurated and tender plaques with scale on the midthigh on initial presentation.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Punch biopsy specimen of an indurated plaque. A prominent deep dermal proliferation of numerous, slender, spindled cells with extension along the interlobular septae of the subcutaneous fat exists. There are minimal lymphocytes in the interlobular septae and a suggestion of mucin between the proliferating spindled cells. The cells stained dually for CD34 and procollagen I. Colloidal iron stain suggested a foci of mucin (original magnification ×20).

Graphic Jump Location

References

Jiménez  SAArtlett  CMSandorfi  N  et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50 (8) 2660- 2666
PubMed Link to Article
Mendoza  FAArtlett  CMSandorfi  NLatinis  KPiera-Velazquez  SJimenez  SA Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35 (4) 238- 249
PubMed Link to Article
Swartz  RDCrofford  LJPhan  SHIke  RWSu  LD Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114 (7) 563- 572
PubMed Link to Article
Cassis  TBJackson  JMSonnier  GBCallen  JP Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 2006;45 (1) 56- 59
PubMed Link to Article
Marckmann  PSkov  LRossen  K  et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17 (9) 2359- 2362
PubMed Link to Article
Marckmann  PSkov  LRossen  KHeaf  JGThomsen  HS Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22 (11) 3174- 3178
PubMed Link to Article
Dundová  ITreska  VSimanek  VMichal  M Nephrogenic fibrosing dermopathy: a case study. Transplant Proc 2005;37 (10) 4187- 4190
PubMed Link to Article
Schmook  TBudde  KUlrich  CNeumayer  HHFritsche  LStockfleth  E Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005;20 (1) 220- 222
PubMed Link to Article
Sadowski  EABennett  LKChan  MR  et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243 (1) 148- 157
PubMed Link to Article
Penfield  JGReilly  RF Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008;21 (2) 129- 134
PubMed Link to Article
Cowper  SE Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15 (6) 785- 790
PubMed Link to Article
Cowper  SEBoyer  PJ Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006;8 (2) 151- 157
PubMed Link to Article
Kucher  CSteere  JElenitsas  RSiegel  DLXu  X Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006;54 (2) (suppl)S31- S34
PubMed Link to Article
Gibson  SEFarver  CFPrayson  RA Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130 (2) 209- 212
PubMed
Saenz  AMandal  RKradin  RHedley-Whyte  ET Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006;449 (3) 389- 391
PubMed Link to Article
Maloo  MAbt  PKashyap  R  et al.  Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006;6 (9) 2212- 2217
PubMed Link to Article
Kay-Wiggan  JMCohen  DJHardy  MA  et al.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48 (1) 55- 60
Link to Article
Jan  FSegal  JMDyer  JLeBoit  PSiegfried  EFrieden  IJ Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003;143 (5) 678- 681
PubMed Link to Article
Introcaso  CEHivnor  CCowper  SWerth  VP Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol 2007;46 (5) 447- 452
PubMed Link to Article
Collidge  TAThomson  PCMark  PB  et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245 (1) 168- 175
PubMed Link to Article
Richmond  HZwerner  JKim  YFiorentino  D Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007;143 (8) 1025- 1030
PubMed Link to Article
Knopp  EACowper  SE Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21 (2) 123- 128
PubMed Link to Article
Gilliet  MCozzio  ABurg  GNestle  FO Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005;152 (3) 531- 536
PubMed Link to Article
Auron  AShao  LWarady  BA Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006;21 (9) 1307- 1311
PubMed Link to Article
Läuchli  SZortea-Caflisch  CNestle  FOBurg  GKempf  W Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004;208 (3) 278- 280
PubMed Link to Article
Kay  JHigh  WA Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008;58 (8) 2543- 2548
PubMed Link to Article
Hubbard  VDavenport  AJarmulowicz  MRustin  M Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003;148 (3) 563- 568
PubMed Link to Article
Ting  WWStone  MSMadison  KCKurtz  K Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139 (7) 903- 906
PubMed Link to Article
Lim  HWHonigsmann  HHawk  JLM Photodermatology.  New York, NY: InformaHealthcare USA; 2007
Dawe  RS Ultraviolet A1 phototherapy. Br J Dermatol 2003;148 (4) 626- 637
PubMed Link to Article
Kafi  RFisher  GJQuan  T  et al.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140 (11) 1322- 1324
PubMed Link to Article
Rodnan  GPLipinski  ELuksick  J Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22 (2) 130- 140
PubMed Link to Article
Takehara  KMoroi  YNakabayashi  YIshibashi  Y Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26 (5) 612- 616
PubMed Link to Article
Scharffetter  KWlaschek  MHogg  A  et al.  UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991;283 (8) 506- 511
PubMed Link to Article
Petersen  MJHansen  CCraig  S Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992;99 (4) 440- 444
PubMed Link to Article
Fisher  GJDatta  SWang  Z  et al.  c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000;106 (5) 663- 670
PubMed Link to Article
McKenna  KEWhittaker  SRhodes  LE  et al. British Photodermatology Group; UK Skin Lymphoma Group, Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006;154 (1) 7- 20
PubMed Link to Article
Dawe  RS Ultraviolet A1 phototherapy. Br J Dermatol 2003;148 (8) 626- 637
Link to Article
Kafi  RFisher  GJQuan  T  et al.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140 (11) 1322- 1324
Link to Article
Mendoza  FAArtlett  CMSandorfi  N  et al.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35 (4) 238- 249
Link to Article
Rodnan  GPLipinski  ELuksick  J Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22 (2) 130- 140
Link to Article
Takehara  KMoroi  YNakabayashi  Y  et al.  Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26 (5) 612- 616
Link to Article
Scharffetter  KWlaschek  MHogg  A  et al.  UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991;283 (8) 506- 511
Link to Article
Petersen  MJHansen  CCraig  S Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992;99 (4) 440- 444
Link to Article
Fisher  GJDatta  SWang  Z  et al.  c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000;106 (5) 663- 670
Link to Article
Kafi  RFisher  GJQuan  T  et al.  UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004;140 (11) 1322- 1324
Link to Article
Knopp  EA Cowper, SE Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21 (2) 123- 128
Link to Article
McKenna  KEWhittaker  SRhodes  LE  et al.  Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006;154 (1) 7- 20
Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 11

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections